Spruce Biosciences (SPRB) Consolidated Net Income (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Consolidated Net Income of -$21.6 million for Q1 2026, down 52.38% year-over-year from -$45.4 million in Q1 2025, and down 94.51% quarter-over-quarter from -$11.1 million in Q4 2025.
Spruce Biosciences (SPRB) Consolidated Net Income (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Consolidated Net Income for 8 consecutive years, with -$21.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income fell 52.38% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at -$43.0 million (up 22.49% YoY), while the FY2025 annual figure was -$38.6 million, up 27.21% from the prior year.
- Consolidated Net Income fell to -$21.6 million in Q1 2026 per SPRB's latest filing, from -$11.1 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$2.1 million in Q2 2025 and bottomed at -$23.5 million in Q4 2024.
- Historically, Consolidated Net Income has averaged -$12.3 million across 5 years, with a median of -$12.2 million in 2022.
- Annual changes were most pronounced in 2024 — Consolidated Net Income slumped 108.37% — and 2025, when it surged 77.49%.
- Spruce Biosciences' Consolidated Net Income stood at -$10.1 million in 2022, then fell by 11.57% to -$11.3 million in 2023, then plunged by 108.37% to -$23.5 million in 2024, then jumped by 52.62% to -$11.1 million in 2025, then slumped by 94.51% to -$21.6 million in 2026.
- Business Quant data shows SPRB's Consolidated Net Income at -$21.6 million in Q1 2026, -$11.1 million in Q4 2025, and -$8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | -16.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.26 Mn |
| Mar 31, 2026 | -21.64 Mn |
| Dec 31, 2025 | -11.12 Mn |
| Sep 30, 2025 | -8.21 Mn |
| Jun 30, 2025 | -2.07 Mn |
| Mar 31, 2025 | -14.20 Mn |
| Dec 31, 2024 | -23.48 Mn |
| Sep 30, 2024 | -8.67 Mn |
| Jun 30, 2024 | -9.18 Mn |
| Mar 31, 2024 | -11.63 Mn |
| Dec 31, 2023 | -11.27 Mn |
| Sep 30, 2023 | -13.73 Mn |
| Jun 30, 2023 | -13.97 Mn |
| Mar 31, 2023 | -13.05 Mn |
| Dec 31, 2022 | -10.10 Mn |
| Sep 30, 2022 | -12.17 Mn |
| Jun 30, 2022 | -12.44 Mn |
| Mar 31, 2022 | -12.19 Mn |
| Dec 31, 2021 | -9.62 Mn |
| Sep 30, 2021 | -18.50 Mn |